|
DK0814790T3
(da)
*
|
1995-02-24 |
2003-11-10 |
Stuart L Weg |
Indgivelse af ketamin med henblik på afgiftning
|
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
EP1551393A4
(en)
|
2002-07-30 |
2010-06-16 |
Peter Migaly |
COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
JP2006510618A
(ja)
*
|
2002-11-18 |
2006-03-30 |
ヤウポン セラピューティクス，インコーポレーテッド |
ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
|
|
US10172810B2
(en)
|
2003-02-24 |
2019-01-08 |
Pharmaceutical Productions, Inc. |
Transmucosal ketamine delivery composition
|
|
EP1611238B1
(en)
|
2003-02-26 |
2009-06-17 |
The John Hopkins University |
Glutamate transport modulatory compounds and methods
|
|
CA2522471A1
(en)
|
2003-04-14 |
2004-10-28 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
|
WO2005102338A1
(en)
|
2004-04-20 |
2005-11-03 |
Pfizer Limited |
Method of treating neuropathic pain using a crth2 receptor antagonist
|
|
WO2006042249A2
(en)
|
2004-10-08 |
2006-04-20 |
Neuromolecular Pharmaceuticals, Inc. |
Methods and compositions for treating migraine pain
|
|
US8058291B2
(en)
|
2005-04-06 |
2011-11-15 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of CNS-related conditions
|
|
US20080096872A1
(en)
|
2004-12-22 |
2008-04-24 |
Friedman Robert S |
Composition for Treatment of Pain Specification
|
|
EP1855686A1
(en)
|
2005-03-01 |
2007-11-21 |
Pfizer Limited |
Use of pde7 inhibitors for the treatment of neuropathic pain
|
|
EP1861003A1
(en)
|
2005-03-04 |
2007-12-05 |
Mentis Cura ehf. |
A method and a system for assessing neurological conditions
|
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
|
KR101529318B1
(ko)
|
2005-12-19 |
2015-06-16 |
파마인 코포레이션 |
치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
|
|
JP2009530385A
(ja)
*
|
2006-03-22 |
2009-08-27 |
マウント シナイ スクール オブ メディシン |
うつ病の治療のためのケタミンの鼻内投与
|
|
EP2029136A4
(en)
|
2006-05-22 |
2010-01-06 |
Vanda Pharmaceuticals Inc |
TREATMENT FOR DEPRESSION DISEASES
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
EP2457571A1
(en)
|
2007-02-01 |
2012-05-30 |
Alan I. Green |
Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
CA2680912C
(en)
|
2007-03-15 |
2017-11-14 |
Auspex Pharmaceuticals, Inc. |
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
|
|
US20080280886A1
(en)
|
2007-05-08 |
2008-11-13 |
Auspex Pharmaceuticals, Inc. |
Substituted ureas
|
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
|
WO2009000038A1
(en)
|
2007-06-28 |
2008-12-31 |
Cnsbio Pty Ltd |
Combination methods and compositions for treatment of neuropathic pain
|
|
CA2698038A1
(en)
|
2007-07-26 |
2009-01-29 |
Entra Pharmaceuticals Inc. |
Systems and methods for delivering drugs
|
|
EP2184986A4
(en)
|
2007-08-06 |
2010-12-15 |
Trinity Lab Inc |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
|
|
NO2200610T3
(pl)
|
2007-09-21 |
2018-06-09 |
|
|
|
EP2254577A1
(en)
|
2007-12-26 |
2010-12-01 |
Eisai R&D Management Co., Ltd. |
Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20140037718A1
(en)
|
2009-03-06 |
2014-02-06 |
George W. Lutz |
Transdermal pain gel
|
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
WO2011053251A1
(en)
|
2009-10-30 |
2011-05-05 |
Ix Biopharma Pte Ltd |
Fast dissolving solid dosage form
|
|
CN102906752B
(zh)
|
2010-01-18 |
2017-09-01 |
艾欧敏达有限公司 |
用于神经生理学数据的加权分析的方法和系统
|
|
WO2013003669A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
|
WO2013088135A1
(en)
|
2011-12-14 |
2013-06-20 |
Astrazeneca Ab |
Gabr-a2 diagnostic
|
|
WO2013138322A1
(en)
*
|
2012-03-12 |
2013-09-19 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
JP2015512418A
(ja)
|
2012-03-30 |
2015-04-27 |
ザ ジェネラル ホスピタル コーポレイション |
うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
|
|
US20120323214A1
(en)
|
2012-05-16 |
2012-12-20 |
Totada R Shantha |
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
|
|
US20140079740A1
(en)
|
2012-08-02 |
2014-03-20 |
ClinPharm Support GmbH |
Oral transmucosal adminstration forms of s-ketamine
|
|
MX2015002378A
(es)
|
2012-08-23 |
2015-09-25 |
Stuart L Weg |
Composicion ansiolitica, formulacion y metodo de uso.
|
|
US8974365B2
(en)
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
|
WO2014100501A1
(en)
|
2012-12-20 |
2014-06-26 |
Sanford-Burnham Medical Research Institute |
Small molecule agonists of neurotensin receptor 1
|
|
US20140274981A1
(en)
|
2013-03-15 |
2014-09-18 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
PH12021552333A1
(en)
|
2013-03-15 |
2022-08-01 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrocholoride
|
|
KR20150135328A
(ko)
|
2013-04-01 |
2015-12-02 |
풀매트릭스 인코퍼레이티드 |
티오트로피움 건조 분말
|
|
US9913803B2
(en)
|
2013-08-26 |
2018-03-13 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
DK3043785T3
(da)
|
2013-09-13 |
2021-11-15 |
Univ Chiba Nat Univ Corp |
Anvendelse af r-ketamin og salt deraf som lægemidler
|
|
CA2936809A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
EP3272338B1
(en)
|
2014-04-17 |
2020-09-09 |
Develco Pharma Schweiz AG |
Oral dosage form of ketamine
|
|
BR112016025910A8
(pt)
|
2014-05-06 |
2021-07-13 |
Univ Northwestern |
uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
|
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
|
WO2016007617A2
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting, Llc. |
Pharmaceutical compounding kit
|
|
US10098854B2
(en)
|
2014-08-13 |
2018-10-16 |
Janssen Pharmaceutica Nv |
Method for the treatment of depression
|
|
EP3193853A1
(en)
|
2014-09-15 |
2017-07-26 |
Janssen Pharmaceutica NV |
VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
|
|
CA2963085C
(en)
|
2014-10-07 |
2023-02-21 |
Lam Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
|
KR102604397B1
(ko)
|
2014-11-04 |
2023-11-21 |
아카디아 파마슈티칼스 인코포레이티드 |
신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
|
|
CA2970065A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
WO2016109427A1
(en)
|
2014-12-31 |
2016-07-07 |
Icahn School Of Medicine At Mount Sinai |
Method of maintaining the anti-depressant effect of ketamine with lithium
|
|
EP3245512A4
(en)
|
2015-01-15 |
2018-05-30 |
Centre for Addiction and Mental Health |
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
US11426366B2
(en)
|
2015-05-15 |
2022-08-30 |
Arizona Board Of Regents On Behalf Of The Universsity Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
AU2016274988A1
(en)
|
2015-06-12 |
2017-12-21 |
Indiana University Research & Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
CN107847469A
(zh)
|
2015-06-27 |
2018-03-27 |
美国神农制药责任有限公司 |
氯胺酮透皮递送系统
|
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
|
KR20180102052A
(ko)
|
2015-10-16 |
2018-09-14 |
노오쓰웨스턴 유니버시티 |
조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
|
|
EP3377050A4
(en)
|
2015-11-17 |
2019-11-20 |
The Trustees of Columbia University in the City of New York |
PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
|
|
US10881637B2
(en)
|
2015-11-17 |
2021-01-05 |
Atlee Solomon |
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
|
|
US20180296478A1
(en)
|
2016-02-12 |
2018-10-18 |
Synergistic Therapeutics, Llc |
Sublingual antidepressant and antianxiety tablet
|
|
US20180042936A1
(en)
|
2016-03-18 |
2018-02-15 |
Genomind, Inc. |
Maintenance therapy using tianeptine
|
|
US20190083420A1
(en)
|
2016-03-25 |
2019-03-21 |
The Uinited States of America, as represented by the Secretary, Department of Health and Human Serv |
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
|
|
WO2017205666A1
(en)
|
2016-05-25 |
2017-11-30 |
National Health Research Institutes |
Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
|
|
SG11201900738YA
(en)
|
2016-07-28 |
2019-02-27 |
Regeneron Pharma |
Gpr156 variants and uses thereof
|
|
CA3030359A1
(en)
|
2016-08-05 |
2018-02-08 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal pharmaceutical powder compositions
|
|
US20180064655A1
(en)
|
2016-09-06 |
2018-03-08 |
Steven Sounyoung Yu |
Hydroxynorketamine Transdermal Patch
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US10905897B2
(en)
|
2016-10-20 |
2021-02-02 |
Neuro-Laser Foundation, Inc. |
Synergistic treatment methodologies using light therapy
|
|
WO2018079693A1
(ja)
|
2016-10-27 |
2018-05-03 |
国立大学法人 千葉大学 |
（ｓ）－ノルケタミンおよびその塩の医薬品としての応用
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
US20180177744A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
|
|
CA3059598A1
(en)
|
2017-04-20 |
2018-10-25 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
CA3105451A1
(en)
|
2017-05-12 |
2018-11-15 |
Indiana University Research And Technology Corporation |
Precision medicine for treating and preventing suicidality
|
|
KR102608479B1
(ko)
|
2017-05-25 |
2023-12-01 |
글리테크 엘엘씨. |
Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
|
|
DE102017112527B4
(de)
|
2017-06-07 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
Schnell zerfallende Schaumwafer mit hohem Flächengewicht
|
|
EP3641742B1
(en)
|
2017-06-23 |
2026-03-25 |
Ketabon GmbH |
Hydroxynorketamine for the use in the treatment of depression
|
|
CN110996912A
(zh)
|
2017-08-20 |
2020-04-10 |
福摩莱克斯医药创新有限公司 |
用于鼻内递送的干粉组合物
|
|
ES2924188T3
(es)
|
2017-09-25 |
2022-10-05 |
Small Pharma Ltd |
Formas sólidas de dosificación oral de derivados de ketamina
|
|
WO2019065900A1
(ja)
|
2017-09-27 |
2019-04-04 |
国立大学法人千葉大学 |
神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
|
|
US12090123B2
(en)
|
2017-10-10 |
2024-09-17 |
Douglas Pharmaceuticals Ltd. |
Extended release pharmaceutical formulation
|
|
WO2019079742A1
(en)
|
2017-10-19 |
2019-04-25 |
Eleusis Benefit Corporation, Pbc |
METHODS AND SYSTEMS FOR IMPROVING THE SAFETY OF PSYCHEDELIC PHARMACOTHERAPIES
|
|
US11491120B2
(en)
|
2017-11-09 |
2022-11-08 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
US20200384188A1
(en)
|
2017-11-14 |
2020-12-10 |
Bexson Biomedical, Inc. |
Systems, devices, formulations and methods for controlled drug delivery
|
|
DE102017129012A1
(de)
|
2017-12-06 |
2019-06-06 |
Lts Lohmann Therapie-Systeme Ag |
Oraler Dünnfilm mit hoher Wirkstoffbeladung
|
|
SG11202005896WA
(en)
|
2017-12-22 |
2020-07-29 |
Janssen Pharmaceuticals Inc |
Esketamine for the treatment of depression
|
|
DK3505157T3
(da)
|
2017-12-29 |
2022-02-28 |
Celon Pharma Sa |
Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
|
|
CN114805139B
(zh)
|
2018-01-10 |
2023-10-20 |
凯瑞康宁生物工程（武汉）有限公司 |
氯胺酮的前药、其组合物和用途
|
|
US10751345B2
(en)
|
2018-02-21 |
2020-08-25 |
AI Therapeutics, Inc. |
Combination therapy with apilimod and glutamatergic agents
|
|
WO2019178484A1
(en)
|
2018-03-16 |
2019-09-19 |
Intra-Cellular Therapies, Inc. |
Novel methods
|
|
WO2019186357A1
(en)
|
2018-03-26 |
2019-10-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
|
US20230390385A1
(en)
|
2018-04-11 |
2023-12-07 |
Fred M. COWAN |
Compositions and Methods for Prevention and Treatment of Immune Complex Disease
|
|
CN118121577A
(zh)
|
2018-05-04 |
2024-06-04 |
感知神经科学公司 |
治疗物质滥用的方法
|
|
WO2019227169A1
(en)
|
2018-05-31 |
2019-12-05 |
The University Of Queensland |
Core-shell polymer nanoparticle
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
IL279713B2
(en)
|
2018-06-27 |
2025-01-01 |
Bioxcel Therapeutics Inc |
Dexmedetomidine-containing layer compositions and methods for their production
|
|
CA3103440A1
(en)
|
2018-06-27 |
2020-01-02 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
EP3829539A4
(en)
|
2018-08-02 |
2022-05-04 |
Taiwan Liposome Company, Ltd. |
DELAYED RELEASE COMPOSITIONS WITH A THERAPEUTIC AGENT FOR THE TREATMENT OF DEPRESSION OR ANXIETY AND USES THEREOF
|
|
US20200038420A1
(en)
|
2018-08-03 |
2020-02-06 |
Enterin, Inc. |
Aminosterol compositions and methods of using the same for treating depression
|
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
EP3628313B1
(en)
*
|
2018-09-28 |
2025-02-12 |
Novohale Therapeutics, LLC |
Ketamine composition for use in a method of treatment of depression by pulmonary administration
|
|
US20210113494A1
(en)
|
2018-10-05 |
2021-04-22 |
Clexio Biosciences Ltd. |
Method Of Treating Post-Traumatic Stress Syndrome
|
|
US20210308040A1
(en)
|
2018-10-26 |
2021-10-07 |
Guangzhou Dazhou Biomedicine Ltd. |
Ketamine oral transmucosal delivery system
|
|
EP3873447A1
(en)
|
2018-10-29 |
2021-09-08 |
Hadasit Medical Research Services and Development Ltd. |
Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
|
|
KR20210110585A
(ko)
|
2018-11-21 |
2021-09-08 |
썰테고 테라퓨틱스 아이엔씨. |
자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
|
|
HUE065684T2
(hu)
|
2019-01-11 |
2024-06-28 |
Alar Pharmaceuticals Inc |
Ketamin-pamoát és alkalmazása
|
|
CA3127607A1
(en)
|
2019-01-23 |
2020-07-30 |
The Regents Of The University Of Michigan |
Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
|
|
WO2020168213A1
(en)
|
2019-02-15 |
2020-08-20 |
Massachusetts Institute Of Technology |
Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
|
|
EP3934632A4
(en)
|
2019-03-05 |
2022-11-23 |
Janssen Pharmaceuticals, Inc. |
Esketamine for the treatment of depression
|
|
US12616706B2
(en)
|
2019-03-07 |
2026-05-05 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
WO2020190997A1
(en)
|
2019-03-18 |
2020-09-24 |
New York Medical College |
Intranasal neuropeptides for use in stress-related impairments
|
|
CA3135552C
(en)
|
2019-04-17 |
2023-09-26 |
Lts Lohmann Therapie-Systeme Ag |
Ketamine containing transdermal therapeutic system comprising free hydroxyl groups
|
|
WO2020223701A1
(en)
|
2019-05-02 |
2020-11-05 |
The Broad Institute, Inc. |
Methods for treating neurodevelopmental disorders
|
|
US12589083B2
(en)
|
2019-05-07 |
2026-03-31 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
WO2020225774A1
(en)
|
2019-05-07 |
2020-11-12 |
Clexio Biosciences Ltd. |
Dosage forms for preventing drug-facilitated assault
|
|
AU2019447630A1
(en)
|
2019-05-31 |
2021-12-23 |
Celon Pharma S.A. |
Electronically supervised administration of a pharmaceutical composition
|
|
PL3976145T3
(pl)
|
2019-05-31 |
2025-04-28 |
Celon Pharma S.A. |
Inhalator do elektronicznie nadzorowanego pozajelitowego podawania kompozycji farmaceutycznej
|
|
EP3979995A4
(en)
|
2019-06-04 |
2023-07-26 |
ADNP Kids Research Foundation |
Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
|
|
EP3923920A4
(en)
|
2019-08-05 |
2022-11-23 |
The Ketamine Research Foundation |
KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
|
|
EP4021432A4
(en)
|
2019-08-28 |
2023-08-16 |
Janssen Pharmaceuticals, Inc. |
ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
|
|
GB201912505D0
(en)
|
2019-08-30 |
2019-10-16 |
Klaria Pharma Holding Ab |
Pharmaceutical formulation
|
|
CN115135363A
(zh)
|
2019-09-13 |
2022-09-30 |
杨森制药公司 |
艾司氯胺酮的鼻内施用
|
|
AU2020358002A1
(en)
|
2019-10-02 |
2022-04-21 |
Praxis Precision Medicines, Inc. |
Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists
|
|
CN114555166A
(zh)
|
2019-10-18 |
2022-05-27 |
奥地利科学技术研究所 |
神经元可塑性的刺激
|
|
WO2021087258A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Indiana University |
Compositions and methods for treating alcohol use disorder or a related condition thereof
|
|
WO2021108801A2
(en)
|
2019-11-15 |
2021-06-03 |
Consegna Pharma, Inc. |
Long acting nmda antagonists
|
|
AU2020387937B2
(en)
|
2019-11-18 |
2026-06-18 |
The United States Government As Represented By The Department Of Veterans Affairs |
Salts of (2R, 6R)-hydroxynorketamine, their crystal forms, and methods of making the same
|
|
US11660305B2
(en)
|
2019-11-19 |
2023-05-30 |
Turtle Bear Holdings, Llc |
Tryptamine compositions for enhancing neurite outgrowth
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
IL294089B1
(en)
|
2019-12-20 |
2026-07-01 |
Alar Pharmaceuticals Inc |
Injectable, long-acting formulations of ketamine pamoate salts
|
|
JP2023507926A
(ja)
|
2019-12-30 |
2023-02-28 |
クレキシオ バイオサイエンシーズ エルティーディー． |
神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
|
|
WO2021137147A1
(en)
|
2019-12-30 |
2021-07-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
PH12022551856A1
(en)
|
2020-01-22 |
2024-01-03 |
Seelos Therapeutics Inc |
Reducing side effects of nmda antagonists
|
|
DE102020106115A1
(de)
|
2020-03-06 |
2021-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
|
|
US20210308075A1
(en)
|
2020-04-07 |
2021-10-07 |
Joseph Habboushe |
Prevention and treatment of virial infections
|
|
IL298334A
(en)
|
2020-05-20 |
2023-01-01 |
Certego Therapeutics Inc |
Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
|
|
EP4157244A4
(en)
|
2020-06-02 |
2024-07-17 |
IX Biopharma Limited |
METHODS OF TREATING MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION
|
|
US11559497B2
(en)
|
2020-06-19 |
2023-01-24 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
US20210401774A1
(en)
|
2020-06-27 |
2021-12-30 |
Robert Brent Turnipseed |
Ketamine protocols and data evaluation for treatment-resistant depression and trauma
|
|
US20220001014A1
(en)
|
2020-07-01 |
2022-01-06 |
Lida Ghaderi |
Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
|
|
US20220040106A1
(en)
|
2020-08-05 |
2022-02-10 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
EP3949956A1
(en)
|
2020-08-06 |
2022-02-09 |
LTS Lohmann Therapie-Systeme AG |
Esketamine-suspension-tts
|
|
CN115942935B
(zh)
|
2020-08-18 |
2025-09-05 |
奥克伍德实验室有限责任公司 |
包括氯胺酮的微球制剂及其制备和使用方法
|
|
WO2022081350A2
(en)
|
2020-09-30 |
2022-04-21 |
Duke University |
Methods for identification, stratification, and treatment of cns diseases
|
|
WO2022096676A1
(en)
|
2020-11-09 |
2022-05-12 |
Lts Lohmann Therapie-Systeme Ag |
Oral thin film
|
|
US20230420110A1
(en)
|
2020-11-18 |
2023-12-28 |
Indiana University Research And Technology Corporation |
Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders
|
|
US11382873B1
(en)
|
2021-01-08 |
2022-07-12 |
Vitalis Analgesics LLC |
Oral administration of ketamine
|
|
IL282188A
(en)
|
2021-04-08 |
2022-11-01 |
Yeda Res & Dev |
Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
|
|
TWI844074B
(zh)
|
2021-08-13 |
2024-06-01 |
凱瑞康寧生技股份有限公司 |
氯胺酮衍生物之醫藥組成物及口服劑型
|
|
US20230144704A1
(en)
|
2021-11-05 |
2023-05-11 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
US20240009145A1
(en)
|
2022-07-07 |
2024-01-11 |
Vitalis Analgesics LLC |
Compositions of aspirin and ketamine
|